All Stories

  1. Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial
  2. Characterisation of paediatric brain tumours by their MRS metabolite profiles
  3. Development of machine learning support for reading whole body diffusion-weighted MRI (WB-MRI) in myeloma for the detection and quantification of the extent of disease before and after treatment (MALIMAR): protocol for a cross-sectional diagnostic test...
  4. DCE-MRI is more sensitive than IVIM-DWI for assessing anti-angiogenic treatment-induced changes in colorectal liver metastases
  5. Early Response to Chemotherapy in Malignant Pleural Mesothelioma Evaluated Using Diffusion-Weighted Magnetic Resonance Imaging: Initial Observations
  6. Quantifying MRI T  1 relaxation in flowing blood: implications for arterial input function measurement in DCE-MRI
  7. MRI texture feature repeatability and image acquisition factor robustness, a phantom study and in silico study
  8. A novel roadmap connecting the 1H-MRS total choline resonance to all hallmarks of cancer following targeted therapy
  9. Noise-Corrected, Exponentially Weighted, Diffusion-Weighted MRI (niceDWI) Improves Image Signal Uniformity in Whole-Body Imaging of Metastatic Prostate Cancer
  10. Monocarboxylate transporter 1 blockade with AZD3965 inhibits lipid biosynthesis and increases tumour immune cell infiltration
  11. Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells
  12. Psychosocial effects of whole-body MRI screening in adult high-risk pathogenicTP53mutation carriers: a case-controlled study (SIGNIFY)
  13. Supervised Machine-Learning Enables Segmentation and Evaluation of Heterogeneous Post-treatment Changes in Multi-Parametric MRI of Soft-Tissue Sarcoma
  14. De novo phosphatidylcholine synthesis is required for autophagosome membrane formation and maintenance during autophagy
  15. Utility of Multi-Parametric Quantitative Magnetic Resonance Imaging for Characterization and Radiotherapy Response Assessment in Soft-Tissue Sarcomas and Correlation With Histopathology
  16. Post-radiotherapy apparent diffusion coefficient (ADC) in children and young adults with high-grade gliomas and diffuse intrinsic pontine gliomas
  17. Methodological consensus on clinical proton MRS of the brain: Review and recommendations
  18. Synthetic 4D-CT of the thorax for treatment plan adaptation on MR-guided radiotherapy systems
  19. Circulating Growth and Sex Hormone Levels and Breast Tissue Composition in Young Nulliparous Women
  20. Super-resolution T2-weighted 4D MRI for image guided radiotherapy
  21. Reproducibility of the lung anatomy under active breathing coordinator control: Dosimetric consequences for scanned proton treatments
  22. Metabolic biomarkers of response to the AKT inhibitor MK-2206 in pre-clinical models of human colorectal and prostate carcinoma
  23. Prospective multicentre evaluation and refinement of an analysis tool for magnetic resonance spectroscopy of childhood cerebellar tumours
  24. Evaluating Imaging Biomarkers of Acquired Resistance to Targeted EGFR Therapy in Xenograft Models of Human Head and Neck Squamous Cell Carcinoma
  25. Abstract 4108: Longitudinal diffusion-weighted MRI assessment of NRAS mutant melanoma response to dual RAF-MEK inhibition reveals differences associated with collagen deposition
  26. PO-0959: Dosimetric Evaluation of Midposition Pseudo-CT for MR-only Lung Radiotherapy Treatment planning
  27. Microstructure Characterization of Bone Metastases from Prostate Cancer with Diffusion MRI: Preliminary Findings
  28. MRI-based Assessment of 3D Intrafractional Motion of Head and Neck Cancer for Radiation Therapy
  29. Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models
  30. Non-Invasive Prostate Cancer Characterization with Diffusion-Weighted MRI: Insight from In silico Studies of a Transgenic Mouse Model
  31. Quantitative evaluation of contrast agent uptake in standard fat-suppressed dynamic contrast-enhanced MRI examinations of the breast
  32. Changes in multimodality functional imaging parameters early during chemoradiation predict treatment response in patients with locally advanced head and neck cancer
  33. Growth Trajectories, Breast Size, and Breast-Tissue Composition in a British Prebirth Cohort of Young Women
  34. Accuracy of screening women at familial risk of breast cancer without a known gene mutation: Individual patient data meta-analysis
  35. MCT1 Inhibitor AZD3965 Increases Mitochondrial Metabolism, Facilitating Combination Therapy and Noninvasive Magnetic Resonance Spectroscopy
  36. Characterisation of fibrosis in chemically-induced rat mammary carcinomas using multi-modal endogenous contrast MRI on a 1.5T clinical platform
  37. T2-Weighted 4D Magnetic Resonance Imaging for Application in Magnetic Resonance–Guided Radiotherapy Treatment Planning
  38. Magnetic Resonance Imaging–Based Assessment of Breast Cancer–Related Lymphoedema Tissue Composition
  39. Detecting human melanoma cell re-differentiation following BRAF or heat shock protein 90 inhibition using photoacoustic and magnetic resonance imaging
  40. Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI
  41. Breast MRI segmentation for density estimation: Do different methods give the same results and how much do differences matter?
  42. In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells
  43. Extracranial Soft-Tissue Tumors: Repeatability of Apparent Diffusion Coefficient Estimates from Diffusion-weighted MR Imaging
  44. Abstract 444: Monocarboxylate transporter 1 inhibition with AZD3965 increases cancer cell dependence on bioenergetic metabolism predicating combination therapy with mitochondrial inhibitors
  45. Pediatric and adult glioblastoma radiosensitization induced by PI3K/mTOR inhibition causes early metabolic alterations detected by nuclear magnetic resonance spectroscopy
  46. A generalized framework unifying image registration and respiratory motion models and incorporating image reconstruction, for partial image data or full images
  47. OC-0303: Evaluation of lung anatomy vs. lung volume reproducibility for scanned proton treatments under ABC.
  48. Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study
  49. Lung volume reproducibility under ABC control and self‐sustained breath‐holding
  50. Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls
  51. P2.05-042 Development of Thoracic Magnetic Resonance Imaging (MRI) for Radiotherapy Planning
  52. MRI Applications, Clinical
  53. Magnetic Resonance Spectroscopy to Study Glycolytic Metabolism During Autophagy
  54. Visualizing whole-body treatment response heterogeneity using multi-parametric magnetic resonance imaging
  55. T 2 -adjusted computed diffusion-weighted imaging: A novel method to enhance tumour visualisation
  56. The BRAF Inhibitor Vemurafenib Activates Mitochondrial Metabolism and Inhibits Hyperpolarized Pyruvate–Lactate Exchange in BRAF-Mutant Human Melanoma Cells
  57. Lactate and choline metabolites are potential biomarkers for monitoring response to mTOR pathway inhibitors in combination with the ALK inhibitor crizotinib in ALK-mutated neuroblastoma
  58. Extended T2-IVIM model for correction of TE dependence of pseudo-diffusion volume fraction in clinical diffusion-weighted magnetic resonance imaging
  59. Blood transfusion during radical chemo-radiotherapy does not reduce tumour hypoxia in squamous cell cancer of the head and neck
  60. A novel approach to evaluate spatial resolution of MRI clinical images for optimization and standardization of breast screening protocols
  61. Time‐resolved angiography with stochastic trajectories for dynamic contrast‐enhanced MRI in head and neck cancer: Are pharmacokinetic parameters affected?
  62. Pre-natal exposures and breast tissue composition: findings from a British pre-birth cohort of young women and a systematic review
  63. Imaging biomarker roadmap for cancer studies
  64. Modulation of renal oxygenation and perfusion in rat kidney monitored by quantitative diffusion and blood oxygen level dependent magnetic resonance imaging on a clinical 1.5T platform
  65. Feasibility and applicability of diffusion-weighted and dynamic contrast-enhanced magnetic resonance imaging in routine assessments of children with high-grade gliomas
  66. Validating a robust double‐quantum‐filtered 1H MRS lactate measurement method in high‐grade brain tumours
  67. Slice Encoding for Metal Artefact Correction in magnetic resonance imaging examinations for radiotherapy planning
  68. Abstract 3973: Diffusion-weighted imaging of bone metastases as treatment response biomarker in prostate cancer
  69. BRAF inhibition promotes BRAF mutant human melanoma cell survival under nutrient-deprived conditions through activation of mitochondrial metabolism
  70. Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer
  71. Development of a temperature‐controlled phantom for magnetic resonance quality assurance of diffusion, dynamic, and relaxometry measurements
  72. Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma
  73. Inter- and Intra-Observer Repeatability of Quantitative Whole-Body, Diffusion-Weighted Imaging (WBDWI) in Metastatic Bone Disease
  74. A computerized volumetric segmentation method applicable to multi-centre MRI data to support computer-aided breast tissue analysis, density assessment and lesion localization
  75. Comparison of Dixon Sequences for Estimation of Percent Breast Fibroglandular Tissue
  76. Repeatability of derived parameters from histograms following non-Gaussian diffusion modelling of diffusion-weighted imaging in a paediatric oncological cohort
  77. Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis
  78. Rapid development of image analysis research tools: Bridging the gap between researcher and clinician with pyOsiriX
  79. Repeatability and sensitivity of measurements in patients with head and neck squamous cell carcinoma at 3T
  80. Evaluating the diagnostic sensitivity of computed diffusion-weighted MR imaging in the detection of breast cancer
  81. Abstract B56: Treatment-induced autophagy increases amino acid uptake and switches glucose addiction to amino acid catabolism in cancer
  82. Abstract B10: Noninvasive pharmacodynamic markers of the dual mTORC1/2 inhibitor AZD2014 in combination with paclitaxel, in cisplatin-resistant ovarian carcinoma xenografts
  83. Response evaluation in mesothelioma: Beyond RECIST
  84. Quality assurance in MRI breast screening: comparing signal-to-noise ratio in dynamic contrast-enhanced imaging protocols
  85. Acting on incidental findings in research imaging
  86. Characterizing Heterogeneity within Head and Neck Lesions Using Cluster Analysis of Multi-Parametric MRI Data
  87. Assessment of repeatability and treatment response in early phase clinical trials using DCE-MRI: comparison of parametric analysis using MR- and CT-derived arterial input functions
  88. Detecting microvascular changes in the mouse spleen using optical computed tomography
  89. Diffusion-weighted MR imaging of metastatic abdominal and pelvic tumours is sensitive to early changes induced by a VEGF inhibitor using alternative diffusion attenuation models
  90. Abstract 2897: Phosphatidylcholine synthesis is required for autophagosome membrane formation and maintenance during autophagy
  91. Abstract 1158: Real-time assessment of uptake and utilization of lactate in intact human breast cancer cells using a 1H-NMR-based assay
  92. Abstract CT138: Translating preclinical observations to the clinic: Combination of the dual m-TORC1/2 inhibitor AZD2014 and paclitaxel in ovarian and lung cancer
  93. Abstract 1130: Unveiling the metabolic response of BRAF mutant melanoma cells to BRAF inhibition
  94. Evaluation of diffusion models in breast cancer
  95. Quantitative Contrast-Enhanced Magnetic Resonance Lymphangiography of the Upper Limbs in Breast Cancer Related Lymphedema: An Exploratory Study
  96. Prospective, longitudinal, multi-modal functional imaging for radical chemo-IMRT treatment of locally advanced head and neck cancer: the INSIGHT study
  97. Diffusion-weighted MR neurography for the assessment of brachial plexopathy in oncological practice
  98. Phase I Study of Nintedanib Incorporating Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Patients With Advanced Solid Tumors
  99. Multi-centre reproducibility of diffusion MRI parameters for clinical sequences in the brain
  100. Single-shot single-voxel lactate measurements using FOCI-LASER and a multiple-quantum filter
  101. Demonstration of the reproducibility of free-breathing diffusion-weighted MRI and dynamic contrast enhanced MRI in children with solid tumours: a pilot study
  102. Acquired resistance to EGFR tyrosine kinase inhibitors alters the metabolism of human head and neck squamous carcinoma cells and xenograft tumours
  103. Magnetic Resonance Imaging Improves Breast Screening Sensitivity in BRCA Mutation Carriers Age ≥ 50 Years: Evidence From an Individual Patient Data Meta-Analysis
  104. First MRI application of an active breathing coordinator
  105. Evaluation of lactate detection using selective multiple quantum coherence in phantoms and brain tumours
  106. High resolution 3D dosimetry for microbeam radiation therapy using optical CT
  107. PRESAGE®as a new calibration method for high intensity focused ultrasound therapy
  108. Use of the temporal median and trimmed mean mitigates effects of respiratory motion in multiple-acquisition abdominal diffusion imaging
  109. 143: Magnetic resonance imaging (MRI) in patients with non-small cell lung cancer (NSCLC) using active breathing coordinator motion control
  110. Investigating the Influence of Flip Angle and k-Space Sampling on Dynamic Contrast-Enhanced MRI Breast Examinations
  111. 540 Vemurafenib alters glucose utilization in BRAF-driven human melanoma cells
  112. Abstract 2451: Insulin-like growth factor-1 receptor (IGF-1R) inhibitors downregulate p53 expression and upregulate the Warburg effect in paediatric glioblastoma cells
  113. Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers
  114. Erratum to: MRI breast screening in high-risk women: cancer detection and survival analysis
  115. Lactate and Choline Metabolites Detected In Vitro by Nuclear Magnetic Resonance Spectroscopy Are Potential Metabolic Biomarkers for PI3K Inhibition in Pediatric Glioblastoma
  116. Poster Presentations
  117. Dichloroacetate induces autophagy in colorectal cancer cells and tumours
  118. SU‐D‐18C‐04: The Feasibility of Quantifying MRI Contrast Agent in Pulsatile Flowing Blood Using DCE‐MRI
  119. Assessment of Treatment Response by Total Tumor Volume and Global Apparent Diffusion Coefficient Using Diffusion-Weighted MRI in Patients with Metastatic Bone Disease: A Feasibility Study
  120. MRI breast screening in high-risk women: cancer detection and survival analysis
  121. Reduced Warburg Effect in Cancer Cells Undergoing Autophagy: Steady- State 1H-MRS and Real-Time Hyperpolarized 13C-MRS Studies
  122. Clinical Proton MR Spectroscopy in Central Nervous System Disorders
  123. Quantitative PET and SPECT performance characteristics of the Albira Trimodal pre-clinical tomograph
  124. Development of a Hybrid Magnetic Resonance and Ultrasound Imaging System
  125. Wireless Accelerometer for MRI-Guided Interventional Procedures
  126. Profiling metabolite changes in the neuronal differentiation of human striatal neural stem cells using 1H-magnetic resonance spectroscopy
  127. Comparison of three reference methods for the measurement of intracellular pH using 31 P MRS in healthy volunteers and patients with lymphoma
  128. The role of pre-treatment diffusion-weighted MRI in predicting long-term outcome of colorectal liver metastasis
  129. Model Free Approach to Kinetic Analysis of Real-Time Hyperpolarized 13C Magnetic Resonance Spectroscopy Data
  130. Noninvasive Phosphorus Magnetic Resonance Spectroscopic Imaging Predicts Outcome to First-line Chemotherapy in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma
  131. Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI
  132. Stacked Autoencoders for Unsupervised Feature Learning and Multiple Organ Detection in a Pilot Study Using 4D Patient Data
  133. SU‐E‐J‐107: SEMAC MRI Metal Artifact Reduction Technique for Radiotherapy Planning Using CT/MRI Fusion
  134. 1 H NMR and hyperpolarized 13 C NMR assays of pyruvate–lactate: a comparative study
  135. MEK1/2 Inhibition Decreases Lactate in BRAF-Driven Human Cancer Cells
  136. Multi-Frame SPRITE: A method for resolution enhancement of multiple-point SPRITE data
  137. Comparison of free-breathing with navigator-controlled acquisition regimes in abdominal diffusion-weighted magnetic resonance images: Effect on ADC and IVIM statistics
  138. Abstract 5640: Picropodophyllin downregulates p53 and increases the Warburg effect in pediatric glioblastoma cells.
  139. Reproducibility of Dynamic Contrast-enhanced MR Imaging: Why We Should Care
  140. Improved intravoxel incoherent motion analysis of diffusion weighted imaging by data driven Bayesian modeling
  141. Optimal age to start preventive measures in women withBRCA1/2mutations or high familial breast cancer risk
  142. First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies
  143. The utility of whole-body diffusion-weighted MRI for delineating regions of interest in PET
  144. Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer
  145. Breast dynamic contrast-enhanced examinations with fat suppression: Are contrast-agent uptake curves affected by magnetic field inhomogeneity?
  146. Abstract P4-11-05: Optimal age to start preventive measures in women with BRCA1/2 mutations or high familial breast cancer risk
  147. Functional imaging in adult and paediatric brain tumours
  148. Advanced Solid Tumors Treated with Cediranib: Comparison of Dynamic Contrast-enhanced MR Imaging and CT as Markers of Vascular Activity
  149. Informatics in Radiology: Development of a Research PACS for Analysis of Functional Imaging Data in Clinical Research and Clinical Trials
  150. Assessment of the dynamic range in dynamic contrast-enhanced magnetic resonance imaging breast examinations
  151. Measurement reproducibility of perfusion fraction and pseudodiffusion coefficient derived by intravoxel incoherent motion diffusion-weighted MR imaging in normal liver and metastases
  152. Whole-Body Diffusion-Weighted MRI: Tips, Tricks, and Pitfalls
  153. 841 Non-invasive Imaging of Response to MEK Inhibition With Selumetinib (AZD6244, ARRY-142886) in a Human Colorectal Cancer Xenograft Using Diffusion-Weighted MRI
  154. Differences in Natural History between Breast Cancers in BRCA1 and BRCA2 Mutation Carriers and Effects of MRI Screening-MRISC, MARIBS, and Canadian Studies Combined
  155. Combination of chemical suppression techniques for dual suppression of fat and silicone at diffusion-weighted MR imaging in women with breast implants
  156. Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer
  157. Abstract B61: Picropodophyllin (PPP) increases glucose metabolism and lactate production in paediatric glioblastoma cells
  158. Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging
  159. Evaluation of distortion correction of diffusion-weighted MR images of human cervix
  160. Neuroendocrine Tumor Liver Metastases: Use of Dynamic Contrast-enhanced MR Imaging to Monitor and Predict Radiolabeled Octreotide Therapy Response
  161. Assessment of colorectal hepatic metastases by quantitative T2 relaxation time
  162. Abstract 2501: Inhibition of the PI3K pathway potentiates temozolomide effects in pediatric glioblastoma and results in alterations in glucose and choline metabolism detected by MRS
  163. Common Breast Cancer Susceptibility Variants in LSP1 and RAD51L1 Are Associated with Mammographic Density Measures that Predict Breast Cancer Risk
  164. Appearances of colorectal hepatic metastases at diffusion-weighted MRI compared with histopathology: initial observations
  165. Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy
  166. An evaluation of motion compensation strategies and repeatability for abdominal 1H MR spectroscopy measurements in volunteer studies and clinical trials
  167. Histone Deacetylase Inhibition Increases Levels of Choline Kinase   and Phosphocholine Facilitating Noninvasive Imaging in Human Cancers
  168. Computerized detection of breast lesions in multi-centre and multi-instrument DCE-MR data using 3D principal component maps and template matching
  169. Computed Diffusion-weighted MR Imaging May Improve Tumor Detection
  170. Exploiting tumor metabolism for non-invasive imaging of the therapeutic activity of molecularly targeted anticancer agents
  171. Quantitative diffusion-weighted (DW) MR imaging of microcapillary perfusion and tissue diffusivity as biomarkers of response of renal cell carcinoma (RCC) to treatment with sunitinib.
  172. Abstract 3788: Autophagy induced by DCA, PI3K inhibition or starvation results in reduced lactate production measured in real-time by DNP 13C MRS
  173. Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies
  174. Abstract 5277: Non-invasive metabolic biomarkers of histone deacetylase inhibition in human colon cancer cells and tumors
  175. Assessment of the effect of haematocrit-dependent arterial input functions on the accuracy of pharmacokinetic parameters in dynamic contrast-enhanced MRI
  176. Analysis of Cancer Metabolism by Imaging Hyperpolarized Nuclei: Prospects for Translation to Clinical Research
  177. Psychological impact and acceptability of magnetic resonance imaging and X-ray mammography: the MARIBS Study
  178. Optimising magnetic resonance imaging for preoperative staging and surgical planning in colon cancer at 1.5 tesla and 3.0 tesla.
  179. A Bayesian hierarchical model for DCE-MRI to evaluate treatment response in a phase II study in advanced squamous cell carcinoma of the head and neck
  180. Phosphorus Magnetic Resonance Spectroscopy Predicts Outcome to Chemotherapy In Patients with Diffuse Large B-Cell Lymphoma: A Prospective International Multicenter Analysis of a Pretreatment Metabolic Biomarker of Response
  181. Noninvasive detection of carboxypeptidase G2 activity in vivo
  182. Dynamic contrast-enhanced MRI of neuroendocrine hepatic metastases: A feasibility study using a dual-input two-compartment model
  183. Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition
  184. The Phosphoinositide 3-Kinase Inhibitor PI-103 Downregulates Choline Kinase α Leading to Phosphocholine and Total Choline Decrease Detected by Magnetic Resonance Spectroscopy
  185. Correlation of the intra-tumor phospholipid-related signatures determined noninvasively by phosphorus and hydrogen MR spectroscopy: An approach to increase the sensitivity and applicability of the technique to predict therapeutic outcome in non-Hodgkin...
  186. Abstract 5083: Inhibition of MEK1/2 signaling in human BRAFV600E melanoma cells reduces glucose uptake and lactate dehydrogenase activity resulting in a time-dependent decrease in lactate production
  187. Robustness of interactive intensity thresholding based breast density assessment in MR-mammography
  188. Virtual conferences becoming a reality
  189. Abstract A72: Assessment of pyuvate dehydrogenase kinase inhibition by dichloroacetate in human colon carcinoma cells by dynamic hyperpolarized 13C MRS and steady state 1H MRS
  190. Abstract A224: Noninvasive PD markers of a pyruvate dehydrogenase kinase inhibitor, dichloroacetate, in human colon carcinoma xenografts
  191. Abstract A228: Noninvasive magnetic resonance spectroscopic PD markers of a minor-groove interstrand cross-linking agent (BN2629) in human colon carcinoma and melanoma xenografts
  192. Metabolic assessment of the action of targeted cancer therapeutics using magnetic resonance spectroscopy
  193. A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy
  194. Assessing the usefulness of a novel MRI-based breast density estimation algorithm in a cohort of women at high genetic risk of breast cancer: the UK MARIBS study
  195. Hyperpolarized 13 C magnetic resonance detection of carboxypeptidase G2 activity
  196. Cancers in BRCA1 and BRCA2 Carriers and in Women at High Risk for Breast Cancer: MR Imaging and Mammographic Features 1
  197. Motion artifact correction in free-breathing abdominal MRI using overlapping partial samples to recover image deformations
  198. Phase-cycled averaging for the suppression of residual magnetisation in SPI sequences
  199. Eligibility for Magnetic Resonance Imaging Screening in the United Kingdom: Effect of Strict Selection Criteria and Anonymous DNA Testing on Breast Cancer Incidence in the MARIBS Study
  200. Quantitative imaging biomarkers in neuro-oncology
  201. Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial
  202. A novel technique to monitor carboxypeptidase G2 expression in suicide gene therapy using19F magnetic resonance spectroscopy
  203. Modulation of choline kinase activity in human cancer cells observed by dynamic31P NMR
  204. Modulating the relaxivity of hyperpolarized substrates with gadolinium contrast agents
  205. An Exploratory Study Into the Role of Dynamic Contrast-Enhanced Magnetic Resonance Imaging or Perfusion Computed Tomography for Detection of Intratumoral Hypoxia in Head-and-Neck Cancer
  206. Changes in choline metabolism as potential biomarkers of phospholipase C 1 inhibition in human prostate cancer cells
  207. Optimizing functional parameter accuracy for breath-hold DCE-MRI of liver tumours
  208. Dynamic contrast-enhanced MRI for prostate cancer localization
  209. Breast cancer screening in women at high risk using MRI
  210. Comparison of Breast Density Assessments Based on Interactive Thresholding and Automated Fast Fuzzy c-means Clustering in Three-Dimensional MR Imaging
  211. 80 POSTER Inhibition of MEK1/2 signalling results in decreased levels of intracellular lactate in human melanoma and colorectal cancer cells as observed with magnetic resonance spectroscopy
  212. A Pilot Study of Compositional Analysis of the Breast and Estimation of Breast Mammographic Density Using Three-Dimensional T1-Weighted Magnetic Resonance Imaging
  213. The value of magnetic resonance spectroscopy in tumour imaging
  214. Heat shock protein 90 inhibitors modulate choline phospholipid profiles and metabolizing enzymes in human melanoma cells
  215. Noninvasive Magnetic Resonance Spectroscopic Pharmacodynamic Markers of a Novel Histone Deacetylase Inhibitor, LAQ824, in Human Colon Carcinoma Cells and Xenografts
  216. Therapeutic Target Metabolism Observed Using Hyperpolarized15N Choline
  217. Quantitative mapping of hepatic perfusion index using MR imaging: a potential reproducible tool for assessing tumour response to treatment with the antiangiogenic compound BIBF 1120, a potent triple angiokinase inhibitor
  218. Computationally efficient vascular input function models for quantitative kinetic modelling using DCE-MRI
  219. Detection of colorectal hepatic metastases using MnDPDP MR imaging and diffusion-weighted imaging (DWI) alone and in combination
  220. BRCA1 Mutation and Young Age Predict Fast Breast Cancer Growth in the Dutch, United Kingdom, and Canadian Magnetic Resonance Imaging Screening Trials
  221. Distortion-correctedT2weighted MRI: a novel approach to prostate radiotherapy planning
  222. O-58 The UK MARIBS study of MRI breast screening: progress on genetic and density projects
  223. Registration of dynamic contrast-enhanced MRI using a progressive principal component registration (PPCR)
  224. Multiscale analysis of MR-mammography data
  225. Selective homonuclear Hartmann–Hahn for13C→13C polarization transfer in solution state NMR
  226. EU Directive 2004/40: field measurements of a 1.5 T clinical MR scanner
  227. Bayesian estimation of pharmacokinetic parameters for DCE-MRI with a robust treatment of enhancement onset time
  228. Predicting Response of Colorectal Hepatic Metastasis: Value of Pretreatment Apparent Diffusion Coefficients
  229. Quantitative evaluation of free-form deformation registration for dynamic contrast-enhanced MR mammography
  230. American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography
  231. Parametric mapping of the hepatic perfusion index with gadolinium-enhanced volumetric MRI
  232. Reference tissue quantification of DCE-MRI data without a contrast agent calibration
  233. Conformational exchange in pimonidazole—a hypoxia marker
  234. Dynamic MRI for imaging tumor microvasculature: Comparison of susceptibility and relaxivity techniques in pelvic tumors
  235. Measurements of occupational exposure to switched gradient and spatially-varying magnetic fields in areas adjacent to 1.5T clinical MRI systems
  236. Reproducibility of reference tissue quantification of dynamic contrast-enhanced data: comparison with a fixed vascular input function
  237. 562 POSTER Inhibition of MEK 1/2 signalling with Cl-1040 in human melanoma cells leads to alterations in phosphocholine metabolism
  238. Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer
  239. A test of performance of breast MRI interpretation in a multicentre screening study
  240. Applications of magnetic resonance spectroscopy in radiotherapy treatment planning
  241. MRI for breast cancer screening
  242. Evaluation of response to treatment using DCE-MRI: the relationship between initial area under the gadolinium curve (IAUGC) and quantitative pharmacokinetic analysis
  243. An investigation of dose calculation accuracy in intensity-modulated radiotherapy of sites in the head & neck
  244. Magnetic resonance spectroscopy (MRS) in the investigation of cancer at The Royal Marsden Hospital and The Institute of Cancer Research
  245. Evaluation of a Prospective Scoring System Designed for a Multicenter Breast MR Imaging Screening Study
  246. Factors influencing the accuracy of biomechanical breast models
  247. Colorectal hepatic metastases: quantitative measurements using single-shot echo-planar diffusion-weighted MR imaging
  248. Minimally Invasive Pharmacokinetic and Pharmacodynamic Technologies in Hypothesis-Testing Clinical Trials of Innovative Therapies
  249. Prediction of Clinicopathologic Response of Breast Cancer to Primary Chemotherapy at Contrast-enhanced MR Imaging: Initial Clinical Results
  250. Magnetic Resonance Imaging Workbench: Analysis and Visualization of Dynamic Contrast-enhanced MR Imaging Data
  251. Application of the chirp z-transform to MRI data
  252. Evaluation of31P high-resolution magic angle spinning of intact tissue samples
  253. Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells
  254. In vivo31P MR spectral patterns and reproducibility in cancer patients studied in a multi-institutional trial
  255. Noninvasive Magnetic Resonance Spectroscopic Pharmacodynamic Markers of the Choline Kinase Inhibitor MN58b in Human Carcinoma Models
  256. Electromagnetic field exposure limitation and the future of MRI
  257. Inversion recovery measurements in the presence of radiation damping and implications for evaluating contrast agents in magnetic resonance
  258. A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points
  259. Adiabatic half-passage pulses for measuring the polarization of highly non-equilibrium spin-systems
  260. Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI
  261. Localized COSY and DQF-COSY1H-MRS sequences for investigating human tibial bone marrow in vivo and initial application to patients with acute leukemia
  262. Dual-contrast echo planar imaging with keyhole: application to dynamic contrast-enhanced perfusion studies
  263. Preliminary dose response study of a gel dosimeter using 2-Hydroxyethyl Methacrylate (HEMA)
  264. Reading Protocol for Dynamic Contrast-enhanced MR Images of the Breast: Sensitivity and Specificity Analysis
  265. Evaluation of radiological features for breast tumour classification in clinical screening with machine learning methods
  266. A complete distortion correction for MR images: II. Rectification of static-field inhomogeneities by similarity-based profile mapping
  267. Identification of biliary metabolites of ifosfamide using 31P magnetic resonance spectroscopy and mass spectrometry
  268. Processing of radical prostatectomy specimens for correlation of data from histopathological, molecular biological, and radiological studies: a new whole organ technique
  269. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS)
  270. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations
  271. Magnetic Resonance Spectroscopy Monitoring of Mitogen-Activated Protein Kinase Signaling Inhibition
  272. A complete distortion correction for MR images: I. Gradient warp correction
  273. Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging
  274. Proceedings of the Engineering and Physical Sciences Research Council Workshop—the development of functional imaging in the diagnosis, management and understanding of childhood brain tumours
  275. Quantitative assessment of the hepatic pharmacokinetics of the antimicrobial sitafloxacin in humans using in vivo19F magnetic resonance spectroscopy
  276. Burst imaging—Can it ever be useful in the clinic?
  277. Implementation and evaluation of CSI-localizedJ cross-polarization for detection of31P magnetic resonance spectra in vivo
  278. Micro-coils for MR spectroscopy by deep silicon etching
  279. SOM-Based Wavelet Filtering for the Exploration of Medical Images
  280. Notices of Duplicate Publication
  281. The dose distribution of low dose rate Cs-137 in intracavitary brachytherapy: comparison of Monte Carlo simulation, treatment planning calculation and polymer gel measurement
  282. Image fusion for dynamic contrast enhanced magnetic resonance imaging
  283. Investigations in vivo of the effects of carbogen breathing on 5-fluorouracil pharmacokinetics and physiology of solid rodent tumours
  284. Methodological standardization for a multi-institutionalin vivo trial of localized31P MR spectroscopy in human cancer research.In vitro and normal volunteer studies
  285. Measurement of the three-dimensional distribution of radiation dose in grid therapy
  286. Investigation of microenvironmental factors influencing the longitudinal relaxation times of drugs and other compounds
  287. Does vascular imaging with MRI predict response to neoadjuvant chemotherapy in primary breast cancer?
  288. Noninvasive Measurements of Capecitabine Metabolism in Bladder Tumors Overexpressing Thymidine Phosphorylase by Fluorine-19 Magnetic Resonance Spectroscopy
  289. Alignment of dynamic contrast-enhanced MR volumes of the breast for a multicenter trial: an exemplar grid application
  290. Multiscale entropy analysis in dynamic contrast-enhanced MRI
  291. Visualization of multivariate image data using image fusion and perceptually optimized color scales based on sRGB
  292. Dose resolution in gel dosimetry: effect of uncertainty in the calibration function
  293. The use of gel dosimetry for verification of electron and photon treatment plans in carcinoma of the scalp
  294. Developing a quality control protocol for diffusion imaging on a clinical MRI system
  295. Evaluation of VEGF expression within breast cancer biopsies & tumour microvasculature assessment by multi-functional dynamic contrast-enhanced MRI
  296. Effects of residual single-quantum coherences in intermolecular multiple-quantum coherence studies
  297. Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy
  298. Nobel Prize in Physiology or Medicine 2003 awarded to Paul Lauterbur and Peter Mansfield for discoveries concerning magnetic resonance imaging
  299. Classification Improvement by Segmentation Refinement: Application to Contrast-Enhanced MR-Mammography
  300. Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials
  301. Magnetic Resonance Spectroscopic Pharmacodynamic Markers of the Heat Shock Protein 90 Inhibitor 17-Allylamino,17-Demethoxygeldanamycin (17AAG) in Human Colon Cancer Models
  302. Human Gallbladder Bile: Noninvasive Investigation in Vivo with Single-Voxel1H MR Spectroscopy
  303. Comparison of polarization transfer sequences for enhancement of signals in clinical31P MRS studies
  304. Ifosfamide pharmacokinetics and hepatobiliary uptake in vivo investigated using single- and double-resonance31P MRS
  305. Could assessment of glioma methylene lipid resonance byin vivo1H-MRS be of clinical value?
  306. Non-invasive study of human gall bladder bilein vivousing1H-MR spectroscopy
  307. Sliding window dual gradient echo (SW-dGRE):T1and proton resonance frequency (PRF) calibration for temperature imaging in polyacrylamide gel
  308. Hyperpolarising 13C for NMR studies using laser-polarised 129Xe: SPINOE vs thermal mixing
  309. Polymer gel measurement of dose homogeneity in the breast: comparing MLC intensity modulation with standard wedged delivery
  310. Potential role of magnetic resonance spectroscopy in assessment of tumour response in childhood cancer
  311. Increased tumour extracellular pH induced by Bafilomycin A1 inhibits tumour growth and mitosis in vivo and alters 5-fluorouracil pharmacokinetics
  312. Radiotherapy treatment planning of prostate cancer using magnetic resonance imaging alone
  313. Validation of nonrigid image registration using finite-element methods: application to breast MR images
  314. Earlyin vivodetection of metabolic response: a pilot study of1H MR spectroscopy in extracranial lymphoma and germ cell tumours
  315. Comparison between radiological and artificial neural network diagnosis in clinical screening
  316. What is the recall rate of breast MRI when used for screening asymptomatic women at high risk?
  317. Comparison of biomechanical breast models: a case study
  318. Finite-element based validation of nonrigid registration using single- and multilevel free-form deformations: application to contrast-enhanced MR mammography
  319. A model to assess SAR for surface coil magnetic resonance spectroscopy measurements
  320. Human rectal adenocarcinoma: Demonstration of1H-MR spectra in vivo at 1.5 T
  321. Apoptosis is associated with triacylglycerol accumulation in Jurkat T-cells
  322. An algorithm for the optimum combination of data from arbitrary magnetic resonance phased array probes
  323. Applications of sliding window reconstruction with cartesian sampling for dynamic contrast enhanced MRI
  324. Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging
  325. Reproducibility of quantitative dynamic MRI of normal human tissues
  326. The effect of Gd-DTPA on T1-weighted choline signal in human brain tumours
  327. Validation of Volume-Preserving Non-rigid Registration: Application to Contrast-Enhanced MR-Mammography
  328. Measuring changes in human tumour vasculature in response to therapy using functional imaging techniques
  329. In vivo hyperpolarized 129Xe NMR spectroscopy in tumors
  330. Effects of Abstinence From Alcohol on the Broad Phospholipid Signal in Human Brain: An In Vivo 31P Magnetic Resonance Spectroscopy Study
  331. Pre-processed image reconstruction applied to breast and brain MR imaging
  332. The quantitative 19 F-imaging of albumin at 1.5 T: a potential in-vivo tool
  333. Numerical evaluation of shaped surface coil sensitivity at 63 MHz
  334. Radio-frequency probe for 1H decoupled 31P MRS of the head and neck region
  335. Effects of Androgen Deprivation on Prostatic Morphology and Vascular Permeability Evaluated with MR Imaging
  336. Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells
  337. Effects of Chronic Alcohol Consumption on the Broad Phospholipid Signal in Human Brain: An In Vivo 31P MRS Study
  338. A modified polymer gel for radiotherapy dosimetry: assessment by MRI and MRS
  339. Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study
  340. Radiation dosimetry using polymer gels: methods and applications.
  341. Implications of respiratory motion for the quantification of 2D MR spectroscopic imaging data in the abdomen
  342. Radiotherapy planning of the pelvis using distortion corrected MR images: the removal of system distortions
  343. 1H decoupling for in vivo 19F MRS studies using the time‐share modulation method on a clinical 1.5 T NMR system
  344. On the oxygenation‐dependent 129Xe T 1 in blood
  345. High-resolution segmented EPI in a motor task fMRI study
  346. The reproducibility of polyacrylamide gel dosimetry applied to stereotactic conformal radiotherapy
  347. Hyperpolarized129Xe NMR as a probe for blood oxygenation
  348. Magnetic resonance spectroscopy in the evaluation of neurotoxicity following cranial irradiation for childhood cancer.
  349. Protocol for a national multi-centre study of magnetic resonance imaging screening in women at genetic risk of breast cancer
  350. Rationale for a national multi-centre study of magnetic resonance imaging screening in women at genetic risk of breast cancer
  351. Surface-coil polarization transfer for monitoring tissue metabolism in vivo
  352. Surface-coil polarization transfer for monitoring tissue metabolism in vivo
  353. Optimized MR imaging for polyacrylamide gel dosimetry
  354. Proton spectroscopic imaging of polyacrylamide gel dosimeters for absolute radiation dosimetry
  355. Breast imaging technology Application of magnetic resonance imaging to angiogenesis in breast cancer
  356. Imaging biochemistry: applications to breast cancer
  357. Dynamic Contrast Enhanced MRI of Prostate Cancer: Correlation with Morphology and Tumour Stage, Histological Grade and PSA
  358. Improving image quality and T1 measurements using saturation recovery turboFLASH with an approximate K-space normalisation filter
  359. Preclinical development of noninvasive vascular occlusion with focused ultrasonic surgery for fetal therapy
  360. SAR and tissue heating with a clinical31P MRS protocol using surface coils, adiabatic pulses, and proton-decoupling
  361. Gallbladder localization of19F MRS catabolite signals in patients receiving bolus and protracted venous infusional 5-fluorouracil
  362. Initial measurements of ifosfamide and cyclophosphamide in patients using31P MRS: Pulse-and-acquire, decoupling, and polarization transfer
  363. 1H decoupling for in vivo19F MRS studies using the time-share modulation method on a clinical 1.5 T NMR system
  364. Proton magnetic resonance spectroscopy (1H-MRS) of the brain following high-dose methotrexate treatment for childhood cancer
  365. Intravenous delivery of hyperpolarized129Xe: a compartmental model
  366. On the oxygenation-dependent129XeT1 in blood
  367. Dynamic contrast-enhanced MRI in the differentiation of breast tumors: User-defined versus semi-automated region-of-interest analysis
  368. Measurement of the extracellular pH of solid tumours in mice by magnetic resonance spectroscopy: a comparison of exogenous19F and31P probes
  369. Signal modulation in1H magnetic resonance spectroscopy using contrast agents: Proton relaxivities of choline, creatine, andN-acetylaspartate
  370. Dynamic contrast‐enhanced MRI in the differentiation of breast tumors: User‐defined versus semi‐automated region‐of‐interest analysis
  371. Experimental 3D dosimetry around a high-dose-rate clinical192Ir source using a polyacrylamide gel (PAG) dosimeter
  372. Comparison and Evaluation of Rigid, Affine, and Nonrigid Registration of Breast MR Images
  373. Dynamics of polymerization in polyacrylamide gel (PAG) dosimeters: (I) ageing and long-term stability
  374. Dynamics of polymerization in polyacrylamide gel (PAG) dosimeters: (II) modelling oxygen diffusion
  375. Comparison of MRI with CT for the radiotherapy planning of prostate cancer: a feasibility study.
  376. Evaluating the effect of rectal distension and rectal movement on prostate gland position using cine MRI
  377. Comparison and evaluation of rigid and nonrigid registration of breast MR images
  378. Magnetic resonance detects metabolic changes associated with chemotherapy-induced apoptosis
  379. Spin-lattice relaxation of laser-polarized xenon in human blood
  380. Perfluorocarbon emulsions as intravenous delivery media for hyperpolarized xenon
  381. Vascular occlusion using focused ultrasound surgery for use in fetal medicine
  382. Perfluorocarbon emulsions as intravenous delivery media for hyperpolarized xenon
  383. Nonrigid registration using free-form deformations: application to breast MR images
  384. Intravascular delivery of hyperpolarized129Xenon forin vivo MRI
  385. Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized31P measurements of response to treatment
  386. Absolute metabolite quantification by in vivo NMR spectroscopy: I. introduction, objectives and activities of a concerted action in biomedical research
  387. Absolute metabolite quantification by in vivo NMR spectroscopy: II. a multicentre trial of protocols for in vivo localised proton studies of human brain
  388. In VivoMultiple Spin Echoes
  389. Measuring diffusion of xenon in solution with hyperpolarized 129Xe NMR
  390. Improving calibration accuracy in gel dosimetry
  391. An investigation into the dosimetry of a nine-field tomotherapy irradiation using BANG-gel dosimetry
  392. Focused ultrasound surgery-induced vascular occlusion in fetal medicine
  393. Influence of pH on the uptake of 5-fluorouracil into isolated tumour cells
  394. MRIW: parametric analysis software for contrast-enhanced dynamic MR imaging in cancer.
  395. A Simple Phantom to Locate the Origin of MRI Ghost Artefacts
  396. Non-rigid registration of breast MR images using mutual information
  397. A pharmacokinetic and pharmacodynamic study In vivo of human HT29 tumours using 19F and 31P magnetic resonance spectroscopy
  398. Implementation and evaluation of frequency offset corrected inversion (FOCI) pulses on a clinical MR system
  399. Reconstruction of elastic modulus distribution from envelope detected B-mode data
  400. Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics
  401. Visual detectability of elastic contrast in real-time ultrasound images
  402. Quantification of phosphorus metabolites in human calf muscle and soft-tissue tumours from localized MR spectra acquired using surface coils
  403. MRI study of hepatic tumours following high intensity focused ultrasound surgery.
  404. Magnetic resonance imaging (MRI): considerations and applications in radiotherapy treatment planning
  405. MRI in the evaluation of late bone marrow changes following bone marrow transplantation
  406. Simultaneous localized 1H STEAM/31P ISIS spectroscopy in Vivo
  407. Measurement of plasma 5-fluorouracil by high-performance liquid chromatography with comparison of results to tissue drug levels observed using in vivo 19F magnetic resonance spectroscopy in patients on a protracted venous infusion with or without inter...
  408. Increased noe enhancement in 1h decoupled 31p mrs
  409. Pharmacokinetics of the 13C labeled anticancer agent temozolomide detected in vivo by selective cross‐polarization transfer
  410. Quantification of signal selection efficiency, extra volume suppression and contamination for ISIS, STEAM and PRESS localized1H NMR spectroscopy using an EEC localization test object
  411. Calculation of Sensitivity Correction Factors for Surface Coil MRS
  412. On doubling the signal in localised stimulated echo measurements
  413. Quality assessment in in vivo NMR spectroscopy: II. A protocol for quality assessment
  414. Quality assessment in in vivo NMR spectroscopy: III. Clinical test objects: Design, construction, and solutions
  415. Quality assessment in in vivo NMR spectroscopy: IV. A multicentre trial of test objects and protocols for performance assessment in clinical NMR spectroscopy
  416. A gradient scheme suitable for localized shimming and in vivo1H/31P STEAM and ISIS NMR spectroscopy
  417. Reducing motion artifacts in in vivo magnetic resonance imaging measurements of relaxation times
  418. International Workshop on Standardization in Clinical Magnetic Resonance Spectroscopy Measurements: Proceedings and recommendations
  419. In vivo monitoring of fluoropyrimidine metabolites
  420. A Phase-Encoded Selection Technique (PEST) for Slice Selection without Resonant-Frequency-Offset Errors
  421. A rapid interleaved method for measuring signal intensity curves in both blood and tissue during contrast agent administration
  422. Phospholipid metabolites, prognosis and proliferation in human breast carcinoma
  423. The non-invasive monitoring of low dose, infusional 5-fluorouracil and its modulation by interferon-α using in vivo 19F magnetic resonance spectroscopy in patients with colorectal cancer: A pilot study
  424. The effect of oestrogen ablation on the phospholipid metabolite content of primary and transplanted rat mammary tumours
  425. Radial diffusion coefficient mapping
  426. Practicalities of localization in animal and human tumours
  427. Fast and accurate measurements of T1 using a multi‐readout single inversion‐recovery sequence
  428. Threshold voltages for hyperbolic secant inversion pulses
  429. A two‐point volume localized T1 measurement sequence for in vivo spectroscopy using a surface coil
  430. Quantitative magnetic resonance spectroscopy by optimized numerical curve fitting
  431. Rapid localization of concave volumes by conformal NMR spectroscopy
  432. A single-shot shimming sequence using low-power RF noise pulses for localized in vivo NMR spectroscopy
  433. The effect of intra‐tumour heterogeneity on the distribution of phosphorus‐containing metabolites within human breast tumours: An In Vitro study using 31P NMR spectroscopy
  434. The phosphocholine and glycerophosphocholine content of an oestrogen-sensitive rat mammary tumour correlates strongly with growth rate
  435. A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer
  436. The water resonance as an alternative pH reference: Relevance to in Vivo31P NMR localized spectroscopy studies
  437. A comparison of in vivo and in vitro 31P NMR spectra from human breast tumours: variations in phospholipid metabolism
  438. A simple method for the restoration of signal polarity in multi‐image inversion recovery sequences for measuring T1
  439. A quantitative analysis of the accuracy of In Vivo pH measurements with 31P NMR spectroscopy: Assessment of pH measurement methodology
  440. Comparison of 5-Fluorouracil pharmacokinetics following intraperitoneal and intravenous administration using in vivo  19F magnetic resonance spectroscopy
  441. An assessment of the sensitivity of in vivo  31P nuclear magnetic resonance spectroscopy as a means of detecting pH heterogeneity in tumours: a simulation study
  442. Installation of an ambient‐temperature control system in a 1.5‐tesla whole body system to facilitate animal studies
  443. The use of an improved inversion pulse with the Spin‐Echo/ inversion‐recovery sequence to give increased accuracy and reduced imaging time for T1 measurements
  444. Conformal NMR spectroscopy: Accurate localization to noncuboidal volumes with optimum SNR
  445. pH calibration curve at 1.5 Tesla
  446. IN-VIVO 31P MAGNETIC RESONANCE SPECTROSCOPY FOR MONITORING TREATMENT RESPONSE IN BREAST CANCER
  447. The performance characteristics of a simulator-based CT scanner
  448. Clinical trials of the prototype Rutherford Appleton Laboratory MWPC positron camera at the Royal Marsden Hospital
  449. Clinical dosimetry for radiotherapy to the breast based on imaging with the prototype Royal Marsden Hospital CT simulator
  450. Measurement of radiation dose to the thyroid using positron emission tomography
  451. The development of high‐efficiency cathode converters for a multiwire proportional chamber positron camera
  452. The design and use of a dual-frequency surface coil providing proton images for improved localization in 3 1 P spectroscopy of small lesions
  453. 3D positron emission tomography: preliminary results
  454. An X-ray detector system and modified simulator providing CT images for radiotherapy dosimetry planning
  455. Constrained deconvolution of SPECT liver tomograms by direct digital image restoration
  456. A clinical evaluation of a prototype positron camera for longitudinal emission tomography
  457. Reconstructions from a Nonstandard CT Scanner
  458. The release rate of37Ar from human subjects following intravenous injection
  459. The measurement of resolution in single photon emission computerised tomography
  460. Tumour localisation in oncology using positron emitting radiopharmaceuticals and a multiwire proportional chamber positron camera; Techniques for 3D deconvolution
  461. A comparison between 180° and 360° data reconstruction in single photon emission computed tomography of the liver and spleen
  462. The spatial resolution of a rotating gamma camera tomographic facility
  463. Preliminary clinical images from a prototype positron camera
  464. A comparison of attenuation correction methods for quantitative single photon emission computed tomography
  465. The retention and release of37Ar from samples of human bone examined in vitro and a review of the implications for argon transfer from bone in vivo
  466. Blood flow measurements and the partition coefficient of 133Xe in bone
  467. A compartmental model for investigating the influence of physiological factors on the rate of washout of133Xe and37Ar from the body
  468. The preparation of 37Ar in sterile solution suitable for injection in vivo
  469. A rotate–translate CT scanner providing cross‐sectional data suitable for planning the dosimetry of radiotherapy treatment
  470. In vivo measurement of calcium by the 37Ar method: a study of the effect of recirculating breath collection systems on the exhalation rate
  471. Total body nitrogen measured by the method: A study of the interfering reactions and the variation of spatial sensitivity with depth
  472. Batch Fabrication of Micro-Coils for MR Spectroscopy on Silicon
  473. Does Registration Improve the Performance of a Computer Aided Diagnosis System for Dynamic Contrast-Enhanced MR Mammography?
  474. A method for the comparison of biomechanical breast models